SINOVAC Biotech Ltd. ("SINOVAC") is a China-based leading biopharmaceutical company that focuses on the research, development, production, and commercialization of vaccines that protect against human infectious diseases.
More2026/08/17
BEIJING, China, August 17, 2026 -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it filed its unaudited fi
BEIJING, China, August X, 2026 — SINOVAC announced that its Serum-Free Rabies Vaccine for Human Use has received a Drug Registration Certificate from China's National Medical Products Administrati
2026/08/06
BEIJING, China, July 31, 2026 — A study evaluating the optimal timing of a booster dose of varicella vaccine among school-aged children has been published in the Chinese Journal of Epidemiology. The r
2026/07/31
BEIJING, China, July 31, 2026 — SINOVAC announced that a large-scale prospective cohort study evaluating the effectiveness of itsvaricella vaccine, live has been published in the peer-reviewed journal
2026/07/31
SINOVAC has undertaken nearly 60 national and regional science and technology
R&D projects; received two State Scientific and Technology Progress Awards
and three national-level institutional technology awards; and published more than
140 SCI papers, many of which were published in top academic journals including
New England Journal of Medicine, The Lancet, Science and Nature, etc.
SINOVAC approved products include: COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac®, Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive®, Hepatitis A Vaccine (Human Diploid Cell) Inactivated - Healive®, Influenza Vaccine (Split Virion), Inactivated - Anflu®, 23-valent Pneumococcal Polysaccharide Vaccine, Varicella Vaccine(Live), Mumps Vaccine(Live), etc.